Seattle Genetics, Inc. (SGEN) Reports Fourth Quarter and Year 2012 Financial Results  
2/13/2013 6:18:34 AM

Seattle Genetics, Inc. (Nasdaq:SGEN) today reported financial results for the fourth quarter and twelve months ended December 31, 2012. The company also highlighted ADCETRIS (brentuximab vedotin) commercialization and clinical development activities, its antibody-drug conjugate (ADC) pipeline and collaborator progress as well as upcoming milestones.